Key result
Intravenous administration of PPMO-6 in CVB3-infected mice resulted in an approximately 2-log10 decrease in myocardial viral titer and significantly reduced cardiac tissue damage at 7 days.
Why the study?
Does PPMO-6 reduce viral titer and cardiac tissue damage in cell cultures and mice infected with Coxsackievirus B3?
Does PPMO-6 reduce viral titer and cardiac tissue damage in cell cultures and mice infected with Coxsackievirus B3?
Effect estimate: ~2-log10 decrease
PPMO-6 potently inhibits Coxsackievirus B3 amplification and reduces cardiac tissue damage in vitro and in vivo, showing promise as a therapeutic candidate for viral myocarditis.
Authors
No takes yet. Share an insight, caveat, or question.
Supports PPMO-6 development for viral myocarditis; leaves open human translation.
Ji et al. (2006) studied Coxsackievirus B3 (CVB3) infection. PPMO-6 vs. Controls was evaluated on Viral titer in the myocardium and cardiac tissue damage at 7 days postinfection (~2-log10 decrease). Intravenous administration of PPMO-6 in CVB3-infected mice resulted in an approximately 2-log10 decrease in myocardial viral titer and significantly reduced cardiac tissue damage at 7 days.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: